HONG KONG – An Australian study has identified a critical molecular feedback loop that helps initiate and drive neuroblastoma, which may result in a badly needed new treatment strategy for the disease, Sydney Children's Hospital and University of New South Wales (UNSW) researchers reported in the Nov. 4, 2015, issue of Science Translational Medicine. Read More

HONG KONG – Through efforts such as China Made 2025, the Thousand Talents program and its five-year plans, China has been putting considerable work into innovation and has emerged as a prolific patent filer that is closing the R&D gap with the U.S. and EU despite a late start in areas such as biotech. Read More

HONG KONG – The CFDA released new regulations to accelerate drug approvals and enhance the integrity of clinical data. At the same time, the regulator is soliciting opinions on a fast-lane approval process for novel drugs. Read More

HONG KONG – The China Securities Regulatory Commission (CSRC) said Friday it plans to lift the four-month ban on IPOs that started during a bout of extreme volatility in the financial markets in Mainland China throughout June and July. Read More

SHANGHAI – For the second time this year, Eli Lilly and Co. entered a strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market, this time with Shanghai-based Wuxi Pharmatech (Cayman) Inc., the well-respected, multifunctional contract research organization (CRO) and contract manufacturer. Read More

NEW DELHI – Controversy over drug price controls continues to pick up speed in India, as pharmaceutical and biotech companies find their bottom lines impacted by unpredictable pricing policies and risk. Read More